Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We 2 | METHODS 2.1 | Data sources and search methods
| INTRODUCTION
Mantle cell lymphoma represents 3%-6% of newly diagnosed nonHodgkin lymphomas. It is characterized as an aggressive lymphoma, but indolent subtypes exist. Most patients are diagnosed with advanced disease (stage III or IV) and are not cured by currently available therapies. 1, 2 The initial response rate to chemoimmunotherapy is high (80%-90%), but relapses are common. There is a wide variation in outcomes with some patients having aggressive presentation, while others have an indolent course. 1 In fit, younger (<65 years) patients, autologous stem cell transplantation (ASCT) is commonly used as a form of consolidation therapy after initial response to chemoimmunotherapy. 2 Data show that upfront ASCT is associated with a median progression-free survival of approximately 7 years and a median 5-year overall survival of 70%-80%. 3 However, these trials are nonrandomized, single-arm studies. Moreover, some patients are not candidates for-ASCT. Therefore, rituximab maintenance (RM) therapy has been explored as a strategy to maintain remission and improve survival in patients who achieve a response to induction therapy regardless of whether ASCT is undertaken.
Data on the use of RM is limited and studies have reported mixed results leading to different practice patterns. To help answer the question of the efficacy of RM therapy, we conducted a systematic review of the literature and performed a meta-analysis, if available data allowed, evaluating the effects of RM therapy on progression-free survival (PFS) and overall survival (OS) of patients with mantle cell lymphoma.
2 | METHODS
| Data sources and search methods
The reporting of this systematic review follows the Preferred Reporting Items for Systematic Review and Meta-Analyses statement. 4 
| Data extraction
Prespecified data elements were extracted from each trial, including baseline characteristics, study design, sample size, interventions used, response rates, and outcome measures (Table 1) . Two reviewers extracted the data from the included studies (T.H. and T.J.), and disagreements were resolved by referring to a third reviewer (C.B.R.).
The number of events in each trial was extracted, when available, based on the intention-to-treat approach.
| Risk of bias assessment and quality of evidence
For randomized clinical trials, we used the Cochrane Collaboration risk of bias assessment tool, focusing on randomization methods, allocation concealment, blinding, and attrition. 5 For observational cohort studies we used the Newcastle-Ottawa quality assessment scale to determine the selection and comparability of study cohorts and methods of ascertainment of outcome. 6 We collected data on exclusions after randomization and whether the primary analysis was performed according to the intention-totreat principle or per protocol. Two reviewers (T.H. and T. J.) independently assessed the studies for methodological quality.
| Data synthesis and statistical analysis
We used the hazard ratio (HR) provided by the included trials to conduct a pooled hazard ratio for survival outcomes. A HR less than 1.0 was in favor of RM therapy. We conducted random-effects metaanalyses using the Der-Simonian-Laird method to pool treatment effects from included studies. We used the I 2 statistic to assess for heterogeneity across the included studies. I 2 value >50% suggest substantial heterogeneity between studies. Two sided P value < .05 suggests statistical significance. We conducted sensitivity analyses using leave-one-out meta-analyses to assess the influence of each study on the overall results.
3 | RESULTS
| Description of studies
In total, 697 titles and abstracts were identified by the screening electronic strategy, of which seven articles describing three randomized clinical trials and four comparative observational studies met the inclusion criteria (Supporting Information Appendix). Main reasons for exclusions were: no comparative arm in observational studies, duplicates, abstracts without full-text publication, and reviews ( Figure 1 ).
The seven studies included a total of 1060 enrolled patients (Table 1) .
| Patient characteristics
All trials included patients with mantle cell lymphoma. Of the three randomized clinical trials, one included patients with relapsed mantle cell and follicular lymphomas, of which only data on mantle cell lymphoma was extracted, 7 and two included patients with newly diagnosed mantle cell lymphoma. 8, 9 Of the four observational studies, only patients with mantle cell lymphoma were included. One study included newly diagnosed patients, 10 and three studies included patients with newly diagnosed disease (~60%-70% of entire cohort) and relapsed disease (~30%-40% of entire cohort for each study).
11-13
In two studies, data on patients with newly diagnosed disease presented separately allowing for extraction of variables for previously untreated patients. 12, 13 Median age ranged between 55 and 60 years across five studies, 9-13 four of which included patients who underwent ASCT.
Two randomized clinical trials included older patients with a median age of 65-70 years. 7, 8 Common inclusion criteria in the randomized trials included stage II-IV disease and ECOG performance status of 0-2. Exclusions included organ dysfunction and central nervous system disease. ond randomization to either RM or interferon alfa. 8 The third trial randomized patients to RM vs. observation after induction chemoimmunotherapy with rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) followed by ASCT.
9
Of the four observational studies, patients were identified from medical records retrospectively and all studies included a comparative arm of observation among the same cohort of patients during the same study period. Three of the four studies evaluated the efficacy of RM therapy after induction chemoimmunotherapy followed by consolidation ASCT, [11] [12] [13] and one study evaluated the efficacy of RM therapy after induction chemoimmunotherapy only (ASCT-ineligible). The four observational studies used variable protocols for RM therapy. Ahmadi et al. used four weekly doses repeated every 6 months over a course of 2 years. 10 The same schedule was used for the majority of patients included in the study by Mei et al. 13 Graf et al. used weekly dosing for 4 weeks every 6 months for 1-2 years, weekly dosing for a single 4 week course, and every 3-month dosing for 2-8 doses. 12 
| Quality of trials
Of the randomized trials, two trials described adequate methods of random sequence generation, and allocation concealment. 7, 8 In all three trials, there was no blinding of the participants. An intention-totreat was performed in two trials. 8, 9 The rate of dropout was low in all trials. None of these studies had incomplete outcome data or selective outcome reporting. Overall, two studies were deemed to be at low risk of bias, and one was deemed at intermediate risk of bias. 7 All three studies received at least partial funding from industry.
Of the observational studies, the selection of study cohorts, comparability and ascertainment of outcomes was deemed adequate in two studies. 12, 13 Comparability of cohorts by statistical controls was not done in two studies. 10, 11 Adequacy of follow-up was unclear in one study. 11 Overall, studies were deemed to be at moderate-to-high risk of bias. All four studies were either not funded or received partial federal funding (Supporting Information Appendix).
| Progression-free survival and overall survival
All seven studies reported PFS results. Five studies reported OS results; two of the three randomized trials, and three of the four observational studies, and were eligible for OS analysis. However, due to substantial heterogeneity among studies, we did not perform an overall meta-analysis OS or PFS.
Analysis according to other variables (eg, maintenance schedule, type of induction chemoimmunotherapy, and age) was not done due to small numbers. Furthermore, we had no access to individual-level data to perform individual-level meta-analysis.
| Meta-analysis of RM in previously untreated ASCTeligible population
Of the four studies in the analysis, three reported data on patients who were previously untreated, which was extracted for this analysis, and one reported data on a cohort of patients with previously untreated and relapsed disease. However, this single study was the smallest and included only 20 patients (30% of cohort and 4% of entire population) with relapsed disease at the time of ASCT. We performed a sensitivity analysis excluding the trial by Le
Gouill et al. 9 to evaluate the effect of RM after ASCT from observational studies only, which were more homogeneous. could not be performed due to unavailability of data.
| DISCUSSION
In this systematic review and meta-analysis, we demonstrate that RM therapy improves both PFS and OS as compared to non-RM strategies in previously untreated patients with mantle cell lymphoma who respond to induction chemoimmunotherapy and undergo ASCT. Furthermore, the data demonstrate that RM improves PFS in patients who are treated with anthracycline-based induction chemoimmunotherapy and are ASCT-ineligible. However, we were unable to perform meta-analysis for OS for patients who are ASCT-ineligible due to paucity of data.
Rituximab has been shown to improve overall response and complete response rates in patients with mantle cell lymphoma. We therefore included studies in this analysis that used induction chemoimmunotherapy with rituximab (90%-100% of patients across included studies). Furthermore, over the last decade, high-dose cytarabine-containing regimens (eg, hyper-CVAD/MA, Nordic regimen, R-DHAP) have been used upfront and are associated with improved survival. 14, 15 Current practice guidelines suggest that in patients who are younger (<65 years) and fit, an intensive, cytarabinecontaining regimen is recommended. The studies in our first meta-analysis in ASCT-eligible patients were conducted across a long period of time and included one randomized trial that used cytarabine-containing induction (ie, R-DHAP), 9 and three observational studies that used cytarabine-containing induction regimens at variable rates (50%-65%). [10] [11] [12] [13] The results, therefore, are not exclusively applicable to cytarabine-based induction (Table 1) .
Based on a CALGB study showing a 2-year PFS rate of 76% and a 5-year OS rate of 64%, ASCT is commonly performed in younger, fit patients after response to induction chemoimmunotherapy in the first-line setting. 16 Of all included studies, four utilized RM therapy after ASCT. Only one is a randomized clinical trial and contributes the highest level of evidence in support of RM in the post-transplant setting. In order to evaluate whether the benefit is retained from homogeneous observational studies only, we performed a sensitivity analysis excluding the trial by Le Gouill et al., which showed the benefit is indeed retained for both OS and PFS.
The maintenance schedule for rituximab varied across studies with earlier studies (2000 s) using 4 weekly doses at several time points, and more recent studies using every 2-3 month dosing for 2-3 years as seen in the trials by Kluin-Nelemans et al. and Le Gouill et al. 8, 9 When applying these results in clinical practice, a schedule of every 2-3 month dosing for 3 years appears to be most appropriate based on the randomized clinical trial by Le Gouill et al. 9 We identified two abstracts of interest that were not included in our meta-analysis due to incomplete data and lack of full peer-review.
The first is an observational study that analyzed data from the Czech 18 These results suggest that the intensity of the induction regimen and undergoing ASCT consolidation are key factors that contribute to the benefit seen with RM therapy.
Our meta-analysis results apply to patients with newly diagnosed, There are limitations to our meta-analysis that should be considered. First, the small number of randomized clinical trials available for analysis (n = 3). Among those, there is considerable heterogeneity, one trial included a small cohort of patients with mantle cell lymphoma treated with fludarabine-based induction, and did not report OS. 7 Another trial included older patients >65 who were ineligible for ASCT, some of whom received fludarabine-based induction as well. 8 Second, due to lack of individual-level data, we were unable to perform meta-analysis of patients treated exclusively with cytarabinebased induction chemoimmunotherapy. Third we were unable to perform a meta-analysis of OS evaluating the benefit of RM after induction chemoimmunotherapy in patients who are ASCT-ineligible.
Fourth, the risk of bias in the observational studies is moderate to high in some. Although we conducted a largely homogeneous meta-analysis, the fact that observational studies were included should be considered when assessing the data.
In summary, our systematic review and meta-analysis suggests that RM therapy is best instituted in the first-line setting and after ASCT consolidation. The role of the induction chemoimmunotherapy regimen appears to be important in contributing to the benefit seen with RM therapy. It remains unclear whether RM therapy is of benefit in patients who are ASCT-ineligible, beyond a possible PFS benefit.
Ongoing randomized trials (eg, NCT01865110) specifically addressing this question are ongoing.
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